MedTrace Logo

Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.

NCT02943707 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-10-25

No results posted yet for this study

Summary

This study evaluates the effect of autologous bone marrow stem cells infusion (ABMSCi) therapy for liver diseases.Treatment group will receive ABMSCi and drugs therapy ,while control group will only receive drugs therapy.

Conditions

Interventions

PROCEDURE

Autologous bone marrow stem cells infusion

Autologous bone marrow stem cells are infused into proper hepatic artery

DRUG

drugs such as Ursodeoxycholic Acid tablets

Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally

Sponsors & Collaborators

  • Wenzhou Medical University

    lead OTHER

Principal Investigators

  • yongping chen · First Affiliated Hospital of Wenzhou Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-10-31
Completion
2020-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943707 on ClinicalTrials.gov